Lupin Ltd., announced today that the Company has entered into a multi-year promotion and marketing agreement for the AeroChamber Plus® line of products with Forest Laboratories, Inc. Under the terms of the agreement, Lupin Pharmaceuticals, Inc, USA, will use its 50 person sales force to promote the product to pediatricians.

AeroChamber Plus® is a Valved Holding Chamber (VHC) device that is used with metered dose inhalers to improve the delivery of medication to the lungs in the treatment of asthma and COPD. Aerochamber Plus® also reduces the deposition of medication in the mouth and throat and makes metered dose inhalers easier for patients to use by reducing the need to coordinate actuation of the inhaler with inhalation. AeroChamber Plus® is the most widely prescribed holding chamber in the United States and has been used by millions of patients since its introduction. Approximately two thirds of AeroChamber Plus® Valved Holding Chamber prescriptions (IMS 2007 data) are written by pediatricians.

“We are happy to strike this alliance with Forest. While the AeroChamber Plus® brand has a strong position in the Valved Holding Chamber market, we believe that this marketing alliance presents a significant opportunity for further growth of the franchise for Forest, resulting in value for both companies” said Dr Kamal Sharma, Managing Director, Lupin Ltd.

This agreement with Forest Laboratories, Inc. reflects Lupin’s commitment to bring value additions to the US market to improve the overall health of the patient population. This alliance will also extend Lupin’s presence in the respiratory segment and help strengthen its franchise with pediatricians.

Tags: calls, daytrading, free calls, intraday, tips

Similar Posts:

• Sharekhan sees 30% upside in Lupin
• Sharekhan puts buy on Lupin
• Buy Lupin, target of Rs 840: Sharekhan
• Lupin Q3FY07-08 cons net profit up 192% to Rs 1809mn
• Buy Lupin, target of Rs 789: Emkay Global